Tetramer immunization and selection followed by CELLISA screening to generate monoclonal antibodies against the mouse cytomegalovirus m12 immunoevasin

Aguilar, Oscar A., Tanaka, Miho, Balaji, Gautham R., Berry, Richard, Rossjohn, Jamie ORCID: https://orcid.org/0000-0002-2020-7522, Lanier, Lewis L. and Carlyle, James R. 2020. Tetramer immunization and selection followed by CELLISA screening to generate monoclonal antibodies against the mouse cytomegalovirus m12 immunoevasin. Journal of Immunology 205 (6) , pp. 1709-1717. 10.4049/jimmunol.2000687

Full text not available from this repository.

Abstract

The generation of reliable mAb of unique and desired specificities serves as a valuable technology to study protein expression and function. However, standard approaches to mAb generation usually involve large-scale protein purification and intensive screening. In this study, we describe an optimized high-throughput proof-of-principle method for the expanded generation, enrichment, and screening of mouse hybridomas secreting mAb specific for a protein of interest. Briefly, we demonstrate that small amounts of a biotinylated protein of interest can be used to generate tetramers for use as prime-boost immunogens, followed by selective enrichment of Ag-specific B cells by magnetic sorting using the same tetramers prior to hybridoma generation. This serves two purposes: 1) to effectively expand both low- and high-affinity B cells specific for the antigenic bait during immunization and 2) to minimize subsequent laborious hybridoma efforts by positive selection of Ag-specific, Ab-secreting cells prior to hybridoma fusion and validation screening. Finally, we employ a rapid and inexpensive screening technology, CELLISA, a high-throughput validation method that uses a chimeric Ag fused to the CD3ζ signaling domain expressed on enzyme-generating reporter cells; these reporters can detect specific mAb in hybridoma supernatants via plate-bound Ab-capture arrays, thereby easing screening. Using this strategy, we generated and characterized novel mouse mAb specific for a viral immunoevasin, the mouse CMV m12 protein, and suggest that these mAb may protect mice from CMV infection via passive immunity.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	American Association of Immunologists
ISSN:	0022-1767
Date of Acceptance:	19 July 2020
Last Modified:	09 Nov 2022 09:31
URI:	https://orca.cardiff.ac.uk/id/eprint/136025

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item